Quantum BioPharma (NASDAQ: QNTM) has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement the Phase 2 trial of Lucid-MS, the company's lead drug candidate for multiple sclerosis (MS). The agreement, announced by the biopharmaceutical company, moves Lucid-MS from planning into execution following FDA clearance of its Investigational New Drug application in August.
The contract covers study start-up activities and related clinical research services. Thermo Fisher's clinical research business, acquired in 2021 for $17.4 billion, is a leading global contract research organization with deep expertise in central nervous system and MS studies. "Following FDA clearance to proceed with the phase 2 study, initiating study start-up activities with a leading global CRO with extensive CNS and MS experience represents an important next step," said Quantum BioPharma CEO Zeeshan Saeed. "We look forward to working with Thermo Fisher, our investigators and clinical research partners as we initiate the Lucid-MS Phase 2 study."
Lucid-MS is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system. Most existing MS drugs work by quieting the immune system, but Lucid-MS aims to protect the nerve's own insulation. "Entering into the Study Start-Up Agreement allows us to begin the operational work required," said Andrzej Chruscinski, Quantum's President of Scientific and Clinical Affairs. "We look forward to working closely with Thermo Fisher and our clinical investigators as the program advances."
The need is significant. MS affects an estimated 3 million people worldwide, including nearly 1 million in the United States. The disease damages myelin, the protective coating around nerve fibers, and is often disabling. Treatment options for progressive forms of MS, which are the focus of the Lucid-MS trial, are limited. A 2023 study in Neurology and Therapy described many patients remaining untreated or continuing to decline despite available therapies. A National MS Society report released this year, drawing on survey responses from more than 2,800 people living with MS, identified urgent unmet needs, including effective treatment of disease progression and therapies that repair myelin damage.
Lucid-MS is an investigational, first-in-class new chemical entity that targets peptidyl arginine deiminase 2 (PAD2), an enzyme implicated in the hypercitrullination of myelin proteins. By inhibiting PAD2, Lucid-MS is being investigated for its potential to protect the integrity of the myelin sheath. In preclinical models, the compound has demonstrated the ability to prevent and reverse measures of myelin degradation, and it showed a favorable safety profile in Phase 1 trials in healthy participants.
The randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive MS, assessing clinical and radiological endpoints tied to disease progression. "We're proud to partner with Quantum BioPharma in advancing their neuro-degenerative clinical program in multiple sclerosis," said Michael Cioffi, vice president and general manager, neuroscience, clinical research, at Thermo Fisher. "Our team brings deep experience in CNS and MS trials, along with an integrated approach that connects strategy and execution to help deliver these complex studies."
The commercial stakes are also notable. Quantum's announcement cites Grand View Research in projecting that the MS therapeutics market will exceed $38 billion by 2030. For more information, visit www.QuantumBioPharma.com. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
Investors and industry leaders should note that while Lucid-MS remains investigational and enrollment dates and trial sites have not been announced, the agreement provides a clear operational path with an experienced partner. This development underscores the growing interest in neuroprotective strategies for neurodegenerative diseases, which could shift treatment paradigms and open new market opportunities. As the trial progresses, its outcomes may influence future research and investment in MS therapies, particularly for progressive forms where unmet need is greatest.
